Cancers and other tumors

Advanced cancer

Pimasertib

A trial to determine if the amount of pimasertib that reaches the bloodstream is the same if taken as a tablet or a capsule

See More Info

Study full name
Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients (EMR200066-013): Study short name
A trial to determine if the amount of pimasertib that reaches the bloodstream is the same if taken as a tablet or a capsule: Drug(s)
Pimasertib: Therapeutic area
Cancers and other tumors: Disease or Medical Indication
Advanced cancer: Sponsor company
EMD Serono, Inc.: Codes
Protocol: EMR200066-013 National Clinical Trial: NCT01992874 EudraCT: Not Applicable: Study Design Summary
: Key Words
adverse events bioavailability blood cancer capsule complete response CPK partial response pharmacokinetics pimasertib progressive disease side effect stable disease tablet tumors: Study dates
November 2013 to February 2015

Ovarian or peritoneal cancer

Pimasertib and SAR245409

Pimasertib plus SAR245409 in Ovarian Cancer

See More Info

Study full name
Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated, Unresectable, Low-Grade Ovarian Cancer: Study short name
Pimasertib plus SAR245409 in Ovarian Cancer: Drug(s)
Pimasertib and SAR245409: Therapeutic area
Cancers and other tumors: Disease or Medical Indication
Ovarian or peritoneal cancer: Sponsor company
EMD Serono, Inc.: Codes
Protocol: EMR200066-012 National Clinical Trial: NCT01936363 EudraCT: Not Applicable: Study Design Summary
: Key Words
adverse event complete response CPK low-grade serous ovarian cancer Ovarian cancer ovaries partial response Peritoneal cancer pimasertib placebo progressive disease SAR245409 side effects stable disease tumors women: Study dates
September 2012 to May 2015

Breast cancer

Gemcitabine (Gemzar®) + Bevacizumab (Avastin®)

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

See More Info

Study full name
A Phase 2 Study of Gemcitabine and Bevacizumab as First-Line Treatment in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Previously Treated With Taxanes: Study short name
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer: Drug(s)
Gemcitabine (Gemzar®) + Bevacizumab (Avastin®): Therapeutic area
Cancers and other tumors: Disease or Medical Indication
Breast cancer: Sponsor company
Eli Lilly and Company: Codes
Protocol: B9E-US-S379 National Clinical Trial: NCT00623233 EudraCT: Not Applicable: Study Design Summary
: Key Words
bevacizumab breast cancer Breast neoplasm chemotherapy gemcitabine HER2 IV infusion pancreas side effects survival tumors women: Study dates
March 2008 to January 2011